Steven Cohen Vaxcyte, Inc. Transaction History

Point72 Asset Management, L.P.

$40.1 Billion
Q1 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 245,317 shares of PCVX stock, worth $8.78 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

245,317

Previous 251,055 2.29%

Holding current value

$8.78 Million

Previous $20.6 Million 54.93%

% of portfolio

0.02%

Previous 0.05%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$37.76 - $92.13 $216,666 - $528,641	-5,738 Reduced 2.29%	245,317 $9.26 Million
Q4 2024 Feb 14, 2025	SELL	$80.97 - $117.93 $8.8 Million - $12.8 Million	-108,741 Reduced 30.22%	251,055 $20.6 Million
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $25.4 Million - $42.1 Million	359,796 New	359,796 $41.1 Million
Q4 2023 Feb 14, 2024	SELL	$45.35 - $63.41 $28.2 Million - $39.4 Million	-621,030 Reduced 95.37%	30,155 $1.89 Million
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $20.8 Million - $24 Million	452,789 Added 228.22%	651,185 $33.2 Million
Q2 2023 Aug 14, 2023	SELL	$34.66 - $54.07 $10.5 Million - $16.4 Million	-302,704 Reduced 60.41%	198,396 $9.91 Million
Q1 2023 May 15, 2023	BUY	$36.27 - $47.2 $7.2 Million - $9.37 Million	198,500 Added 65.6%	501,100 $18.8 Million
Q4 2022 Feb 14, 2023	SELL	$20.58 - $47.95 $2.47 Million - $5.76 Million	-120,200 Reduced 28.43%	302,600 $14.5 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $9.17 Million - $12.1 Million	422,800 New	422,800 $10.1 Million

Others Institutions Holding PCVX

# of Institutions

345

Shares Held

136M

Call Options Held

348K

Put Options Held

250K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $2.12B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account